Introduction This phase I study investigated the activity of the irreversible pan-human
epidermal growth factor receptor inhibitor dacomitinib in combination with the mesenchymal …

Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting
in tumor microenvironment and these factors are also potential targets of antiangiogenic …

Noninvasive genotyping of driver genes and monitoring of tumor dynamics help make better
personalized therapeutic decisions. However, neither PCR-based assays nor amplicon …

Introduction Central nervous system (CNS) metastases are common in non–small cell lung
cancer (NSCLC), yet clinical trials of new drugs in advanced NSCLC have varying inclusion …

Introduction: Tumour molecular profiling has been at the crossroads of large-scale
integrative genomic studies and major clinical trials over the past 5 years and has provided …

Genotype-based selection of patients for targeted therapies has had a substantial impact on
the treatment of non-small cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) …

Expert consensus guidelines have defined minimum requirements for routine testing and
identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions …

Background Clinical outcomes of anaplastic lymphoma kinase (ALK)-rearranged non-small
cell lung cancer according to ALK fusion variants are not clear. We aimed to investigate the …

Targeted therapies have induced high response rates and improved survival in patients with
cancer. However, the long-term effectiveness of targeted therapies has been limited by the …

Recent advances in the molecular characterization of cancers have triggered interest in
developing a new taxonomy of disease in oncology with the goal of using the molecular …